Navigation Links
MSU launches groundbreaking drug trial in Africa
Date:2/15/2013

Determined to bring relief to seizure victims, a Michigan State University research team this month begins a groundbreaking clinical drug trial that could help prevent a quarter-million African children from developing epilepsy each year.

It will be the first test of the anti-seizure medication levetiracetam, or LVT, for controlling seizures caused by cerebral malaria, a severe form of the disease that affects brain function in some three million children, mostly in sub-Saharan Africa.

About one in 10 children who survive cerebral malaria are left with epileptic seizures, said the trial's lead researcher Gretchen Birbeck, a professor of neurology and ophthalmology in the College of Osteopathic Medicine.

"This trial is aimed at improving seizure control with the hope of finding a path toward epilepsy prevention," Birbeck said. "Since oral LVT is relatively affordable for short-term use and feasibly could be delivered in resource-limited settings, this therapy could potentially be scaled up for broad use throughout malaria endemic African countries."

The trial will include about 40 children in Malawi. If all safety standards are met, dosage will be increased until 75 percent of the children are free of seizures for 24 hours.

A wireless EEG monitoring device the size of a deck of cards will tell the researchers if LVT is keeping the children seizure-free. Developed by New York-based biotechnology firm BioSignal Group, the device can be worn on the child's arm and transfers data in real-time to a computer, where it quickly can be analyzed and shared with colleagues.

"Unfortunately, many children with cerebral malaria continue to have seizures with no clinical evidence that seizures are occurring, but their brains still are being affected," said Birbeck, who also is director of MSU's International Neurologic and Psychiatric Epidemiology Program. "To evaluate the effectiveness of LVT, we need continuous EEG monit
'/>"/>

Contact: Andy McGlashen
andy.mcglashen@cabs.msu.edu
517-355-5158
Michigan State University
Source:Eurekalert

Page: 1 2

Related biology news :

1. NTU launches new centre to develop new eye-deas for occular therapeutics
2. Elsevier launches new open access journal: Molecular Metabolism
3. Canada launches first gene therapy trial for Fabry disease
4. Elsevier launches new journal: Journal of Unconventional Oil and Gas Resources
5. F1000Research, the first Open Science publisher, launches following a successful beta testing phase
6. Wake Forest Baptist Medical Center Launches Wake Forest Innovations
7. Neurotechnology Launches SkyBiometry Spin-off Company to Deliver SaaS Biometric Identification and Feature Analysis
8. Elsevier launches new open access journal -- Case Studies in Engineering Failure Analysis
9. Gene sequencing project identifies abnormal gene that launches rare childhood leukemia
10. Smithsonian launches global marine biodiversity project with $10 million donation
11. Rice launches sweeping Energy and Environment Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
(Date:7/11/2014)... eastern New South Wales, Australia when NASA,s Aqua satellite ... on July 11 (12:35 p.m. local time/11:35 p.m. EDT ... South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) ... and spotted smoke (light brown) from various fires. Actively ... in red. , The New South Wales, Australia Government ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... and treatment of breast cancer, the disease remains a ... technology under investigation at the Biodesign Institute at Arizona ... cell nuclear structure, the molecular biosignature of cancer, thus ... detection of the disease. The team, led by ...
... half years since Adam Bogdanove, professor at Iowa State University ... Matthew Moscou, a former graduate student in that department, discovered ... and bind specific sequences in plant genomes, researchers worldwide have ... was first shown that the proteins can be fused to ...
... Scientists have uncovered a lot about the Earth,s greatest ... rapid climate change wiped out nearly all marine species and ... a new culprit likely involved in the annihilation: an influx ... looked to see if mercury was a potential culprit. This ...
Cached Biology News:Cell-CT: A new dimension in breast cancer research 2Cell-CT: A new dimension in breast cancer research 3Cell-CT: A new dimension in breast cancer research 4ISU scientist helps find structure of gene-editing protein named Method of the Year 2Earth's massive extinction: The story gets worse 2
(Date:7/12/2014)... 2014 This report covers ... in the life science industry. Continuous innovation ... reagents market towards remarkable growth. The stakeholders ... of life science reagents. , Brows full ... . , The global life science reagents ...
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
(Date:7/11/2014)... 11, 2014 , Not for release, ... or from any jurisdiction where to do so would constitute ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ...  Shire confirms it has held a meeting with representatives of ... without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... , July 11, 2014 Research ... "International Transfection Technology Market - Global Industry Analysis, Size, ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... introduce nucleic acids (either DNA or RNA) into cells. ... mutation of cancer cells and protein metabolism by affecting ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2
... 7 When leading contract research,organization Pharm-Olam International (POI, ... voice-over Internet protocol (VoIP),system that would better serve the ... catastrophic., POI initially selected a local vendor to ... immediately clear the solution was a bigger problem,than the ...
... LifeQuest World Corporation,(OTC Bulletin Board: LQWC) is pleased ... ImmunXT, their Immune System enhancement supplement, has,been released ... of March 2008.,ImmunXT has been proclaimed as "the ... (US Patent #7,205,284 B2),is a bio-active Micro-algae Complex ...
... Eastern Time -, SOUTH SAN FRANCISCO, Calif., May ... biopharmaceutical company focused,on oncology, today reported on its corporate ... 31, 2008., "During the first quarter, we made ... data to demonstrate the potential of,picoplatin as a new ...
Cached Biology Technology:Pharm-Olam Finds VoIP Solution in Taridium LLC 2LifeQuest World Launches Immune System Boosting Supplement to the North American Market 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update 9
... PP2A1, purified Formulation: 50mM Tris-HCl, ... Brij-35, 0.2mM PMSF, 1mM benzamidine, ... Properites: PP2A1 (Protein Phosphatase 2A1) ... ammonium sulfate precipitation, QSepharose,amino-hexyl agarose, ...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
Biology Products: